S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow-up

Berenice M. Lang, Panagiotis Balermpas, Andrea Bauer, Andreas Blum, G. Felix Brölsch, Thomas Dirschka, Markus Follmann, Jorge Frank, Bernhard Frerich, Klaus Fritz, Axel Hauschild, Ludwig M. Heindl, Hans Peter Howaldt, Stephan Ihrler, Vinodh Kakkassery, Bernhard Klumpp, Albrecht Krause-Bergmann, Christoph Löser, Markus Meissner, Michael M. SachseMax Schlaak, Michael P. Schön, Lutz Tischendorf, Michael Tronnier, Dirk Vordermark, Julia Welzel, Michael Weichenthal, Susanne Wiegand, Roland Kaufmann, Stephan Grabbe*

*Corresponding author for this work


Basal cell carcinoma (BCC) is the most common malignant tumor among fair-skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow-up of patients with basal cell carcinoma.
Original languageEnglish
JournalJDDG - Journal of the German Society of Dermatology
Issue number2
Pages (from-to)214-230
Number of pages17
Publication statusPublished - 01.02.2019

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow-up'. Together they form a unique fingerprint.

Cite this